Total Wealth Planning & Management Inc. Purchases Shares of 4,704 Gilead Sciences, Inc. $GILD

Total Wealth Planning & Management Inc. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 4,704 shares of the biopharmaceutical company’s stock, valued at approximately $577,000.

Several other hedge funds and other institutional investors have also modified their holdings of GILD. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in Gilead Sciences by 52.1% in the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock valued at $8,713,000 after buying an additional 26,882 shares during the period. Cookson Peirce & Co. Inc. raised its holdings in Gilead Sciences by 249.1% in the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after buying an additional 7,168 shares during the period. NewEdge Wealth LLC raised its holdings in Gilead Sciences by 2.9% in the third quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock valued at $75,962,000 after buying an additional 17,284 shares during the period. Nordea Investment Management AB raised its holdings in Gilead Sciences by 16.5% in the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after buying an additional 726,101 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Gilead Sciences by 4.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 161,155 shares of the biopharmaceutical company’s stock valued at $17,888,000 after buying an additional 6,680 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Lakefront completed the acquisition of Ouro Medicines, expanding the company’s inflammation pipeline and adding gamgertamig, a potential first-in-class T cell engager for autoimmune diseases. This can support the stock by broadening long-term growth opportunities. Article Title
• Positive Sentiment: Gilead reported positive Phase 3 IDEAL trial results for Livdelzi in primary biliary cholangitis, including improved ALP normalization, which strengthens the case for a larger liver disease franchise and potential regulatory momentum. Article Title
• Positive Sentiment: Additional coverage highlighted favorable Livdelzi data and the company’s expanding liver and oncology footprint, which may reinforce confidence in Gilead’s growth pipeline. Article Title
• Neutral Sentiment: Coverage also noted that Gilead is drawing investor attention and being compared with other healthcare names, but these articles are more commentary than a direct new catalyst. Article Title
• Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan. While routine, insider selling can still weigh on sentiment for some investors. Article Title

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock valued at $9,047,570 in the last three months. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of several research reports. Deutsche Bank Aktiengesellschaft raised their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Leerink Partners cut their price target on shares of Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Truist Financial reissued a “buy” rating and set a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Scotiabank boosted their price target on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, February 11th. Finally, Sanford C. Bernstein reissued an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a research report on Wednesday, February 11th. Twenty-six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $156.93.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $129.18 on Friday. The stock’s 50 day moving average price is $134.56 and its 200 day moving average price is $134.34. The firm has a market capitalization of $160.39 billion, a PE ratio of 17.60 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a one year low of $104.46 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.